Tissue-directed pharmacokinetics
- PMID: 1656743
- DOI: 10.1016/0002-9343(91)90394-d
Tissue-directed pharmacokinetics
Abstract
Azalide antibiotics demonstrate pharmacokinetics distinct from all antibacterial agents in common use. Following oral absorption, conventional oral antibiotics diffuse through serum and interstitial compartments and are eliminated rapidly. A minimal to moderate degree of intracellular penetration may be observed. The pharmacokinetics of azithromycin, the first azalide, are characterized by a rapid and extensive movement of the drug from the serum into intracellular compartments. A dynamic equilibrium exists between the intracellular, interstitial, and serum compartments, with predominant flux into tissue sites. Azithromycin is concentrated to a high degree within phagocytes and transported by chemotactic mechanisms to the site of infection. High concentrations of azithromycin are found in pulmonary, genital, and lymphatic tissues. Azithromycin's serum levels decline in a polyphasic manner with a terminal half-life of approximately 60 hours. These kinetics allow azithromycin to be administered once daily. It is predicted that after drug administration for 5 days, therapeutic levels of azithromycin will be maintained at the tissue sites of infection for an additional 4-7 days. Consideration of the extravascular pharmacodynamics of azithromycin is necessary when making predictions regarding its therapeutic application.
Similar articles
-
Azithromycin: the first azalide antibiotic.Ann Pharmacother. 1992 Oct;26(10):1253-61. doi: 10.1177/106002809202601014. Ann Pharmacother. 1992. PMID: 1330097 Review.
-
The pharmacokinetics of azithromycin and their clinical significance.Eur J Clin Microbiol Infect Dis. 1991 Oct;10(10):807-12. doi: 10.1007/BF01975832. Eur J Clin Microbiol Infect Dis. 1991. PMID: 1662623 Review.
-
Clinical microbiology of azithromycin.Am J Med. 1991 Sep 12;91(3A):12S-18S. doi: 10.1016/0002-9343(91)90395-e. Am J Med. 1991. PMID: 1656736 Review.
-
Pharmacokinetics and pharmacodynamics of intravenous and oral azithromycin: enhanced tissue activity and minimal drug interactions.Ann Pharmacother. 1998 Jul-Aug;32(7-8):785-93. doi: 10.1345/aph.17299. Ann Pharmacother. 1998. PMID: 9681095 Review.
-
Azithromycin. A review of its antimicrobial activity, pharmacokinetic properties and clinical efficacy.Drugs. 1992 Nov;44(5):750-99. doi: 10.2165/00003495-199244050-00007. Drugs. 1992. PMID: 1280567 Review.
Cited by
-
Issues in pharmacokinetics and pharmacodynamics of anti-infective agents: distribution in tissue.Antimicrob Agents Chemother. 2004 May;48(5):1441-53. doi: 10.1128/AAC.48.5.1441-1453.2004. Antimicrob Agents Chemother. 2004. PMID: 15105091 Free PMC article. Review. No abstract available.
-
Distribution of azithromycin in plasma and tonsil tissue after repeated oral administration of 10 or 20 milligrams per kilogram in pediatric patients.Antimicrob Agents Chemother. 2002 May;46(5):1594-6. doi: 10.1128/AAC.46.5.1594-1596.2002. Antimicrob Agents Chemother. 2002. PMID: 11959610 Free PMC article. Clinical Trial.
-
Effect of topical azithromycin on corneal innate immune responses.Invest Ophthalmol Vis Sci. 2011 Apr 19;52(5):2525-31. doi: 10.1167/iovs.10-5658. Invest Ophthalmol Vis Sci. 2011. PMID: 21296809 Free PMC article.
-
Three month treatment of reactive arthritis with azithromycin: a EULAR double blind, placebo controlled study.Ann Rheum Dis. 2004 Sep;63(9):1113-9. doi: 10.1136/ard.2003.010710. Ann Rheum Dis. 2004. PMID: 15308521 Free PMC article. Clinical Trial.
-
Comparison between Single Dose Azithromycin and Six Doses, 3 Day Norfloxacin for Treatment of Cholera in Adult.Int J Biomed Sci. 2014 Dec;10(4):248-51. Int J Biomed Sci. 2014. PMID: 25598755 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources